Market Research Report - 247082
Global Central Nervous System Drugs Market 2011-2015
|Published by||TechNavio (Infiniti Research Ltd.)|
|Published||Content info||56 Pages|
|Global Central Nervous System Drugs Market 2011-2015|
|Published: July 13, 2012||Content info: 56 Pages||
This publication has been discontinued on November 12, 2015.
TechNavio's analysts forecast the Global Central Nervous System Drugs market to grow at a CAGR of -3.2 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing size of aging population. The Global EEG/EMG Equipment market has also been witnessing the trend of novel molecules, launched to treat central nervous system disorders effectively. However, patent expiration of key drugs could pose a challenge to the growth of this market.
TechNavio's report, the Global Central Nervous System Drugs Market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Central Nervous System Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this market space include AstraZeneca plc, Eli Lilly & Co., Johnson & Johnson Ltd., and Pfizer Inc. Other vendors mentioned in the report: Abbott Laboratories, Sanofi S.A., Bristol-Myers Squibb Co., Eisai Co. Ltd., UCB Pharma, Merck & Co. Inc., Schering-Plough Corp., Shire plc, and Cephalon Inc.
You can request one free hour of analyst time when you purchase this report. Details provided within the report.